Who Are We?

Our Company in Brief

Health Outcomes Sciences is propelling the practice of precision medicine through its patented content enablement platform, ePRISM®, which translates scientific models into automated evidence-based decision support solutions.

By helping health and life science organizations — as well as allied technology partners — deliver the power of personalized predictive science at the point of care, the company facilitates significant and measurable improvements in clinical and financial outcomes, variations in care, appropriate use and rational consumption of resources.

The company’s solutions are specialty agnostic, scalable at the enterprise level and employ a cloud-hosted software-as-a-service (SaaS) business model.

Fast Facts

  • Health Outcomes Sciences founded in 2004, commercially launched in 2009.
  • ePRISM® conceived by renowned cardiovascular researchers, John Spertus, MD, MPH, FACC and Gabe Soto, MD, PhD.
  • Exclusive partnership with American College of Cardiology for delivery of NCDR® predictive risk models at the point of care.
  • Six technology-related patents governing use of mathematical models for projecting clinical outcomes.
  • Corporate headquarters in Greater Kansas City metropolitan area.
  • 2016 and 2015 Becker’s Hospital Review ‘150 Great Places to Work in Healthcare.’
  • 2015 and 2014 Kansas City Business Journal ‘Best Places to Work.’

Validated by Scientific Research

Our patented ePRISM® technology platform was central to a landmark cohort study that demonstrated substantive correlations between pre-procedure risk stratification and post-procedure complications.1 The study was funded through grants awarded by American Heart Association and National Heart, Lung, and Blood Institute.

Employing ePRISM® in conjunction with a predictive model authored by American College of Cardiology NCDR®, nine study sites prospectively assessed the bleeding risk of patients undergoing percutaneous coronary intervention (PCI). Through use of appropriate bleeding avoidance strategies (bivalirudin, radial entry and/or vascular closure device) in response to patients at higher risk, study sites realized a 59% reduction in incidence of post-procedure bleeding complications.

To allow for contemporary trends in the generalized use of bleeding avoidance strategies, study sites were matched to control sites with equivalent institutional and individual physician characteristics. Comparative results showed a 44% reduction in the probability of bleeding at study sites versus 9% at control sites.

Before the onset of the study, it had been well established that bleeding is one of the most common non-cardiac complications of PCI and is associated with increased mortality, morbidity and cost.2 Findings of the study highlight the potential for predictive models to markedly improve care.

[Get Full Publication]

1 Spertus, JA, et al. Precision medicine to improve use of bleeding avoidance strategies and reduce bleeding in patients undergoing percutaneous coronary intervention: prospective cohort study before and after implementation of personalized bleeding risks. BMJ 2015;350:h1302
2 Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004;292:2096-104

Our Mission

Our mission is to translate evidence-based, research-derived content into transformative technology solutions, and advance the use of predictive science as a new vital sign for clinical decision-making.

Our Vision

Our vision is to evolve the practice of personalized precision medicine around the globe, reducing unwarranted variances in care, improving the quality and appropriateness of care, and effecting better clinical and financial outcomes.